文献速递肝病消化道肿瘤与早癌

自身免疫性肝炎患者癌症风险增加:丹麦全国队列研究

Increased Cancer Risk in Autoimmune Hepatitis: A Danish Nationwide Cohort Study.
PubMed 文献 · Am J Gastroenterol · 2022-01-01

该研究基于丹麦全国登记数据,纳入1994至2018年诊断的1805例自身免疫性肝炎(AIH)患者及16617名年龄性别匹配的对照,评估癌症累积风险与风险比。结果显示AIH患者10年任何癌症风险为13.6%,风险比1.5;肝硬化及免疫抑制治疗时间延长与癌症风险升高相关。

要点

  • AIH患者10年任何癌症风险13.6%,较匹配对照风险比1.5。
  • AIH患者10年肝细胞癌风险0.5%,结直肠癌风险1.6%(RR 2.1),非黑色素瘤皮肤癌风险4.0%(RR 1.8)。
  • 合并肝硬化者癌症风险更高(HR 1.3),免疫抑制治疗每增加一年风险增加1.05倍。

核心结论

  • 自身免疫性肝炎与10年癌症风险较年龄性别匹配对照增加1.5倍相关。
  • 在AIH患者中,肝硬化与癌症风险升高相关,且风险随免疫抑制治疗时间延长而轻度增加。

研究设计与样本

  • 基于丹麦全国医疗登记系统的全国性队列研究,纳入1994至2018年诊断的1805例AIH患者和16617名年龄性别匹配的对照。

主要发现

  • AIH患者10年任何癌症风险为13.6%(95%CI 11.7-15.6),对照风险比为1.5(95%CI 1.3-1.7)。
  • AIH患者10年肝细胞癌风险为0.5%(95%CI 0.2-1.1)。
  • AIH患者10年结直肠癌风险为1.6%(95%CI 1.0-2.5),风险比2.1(95%CI 1.3-3.5)。
  • AIH患者10年非黑色素瘤皮肤癌风险为4.0%(95%CI 3.0-5.3),风险比1.8(95%CI 1.3-2.5)。
  • 在AIH患者中,肝硬化者癌症风险更高(风险比1.3,95%CI 1.0-1.7),免疫抑制治疗每增加一年风险增加1.05倍(95%CI 1.0-1.1)。

临床怎么用

  • 对AIH患者应关注总体癌症风险,尤其合并肝硬化或长期免疫抑制治疗者。
  • 可考虑针对结直肠癌和非黑色素瘤皮肤癌进行适当监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Autoimmune hepatitis (AIH) is a chronic inflammatory liver disease and as such may increase the risk of cancer. We examined cancer risks in a nationwide cohort of patients with AIH. METHODS: This study was based on nationwide Danish healthcare registries. We identified all persons diagnosed with AIH between 1994 and 2018. We included 1805 patients with AIH and 16,617 age- and sex-matched population controls. We estimated cumulative risks of cancers and risk ratios (RRs) between patients and controls. Within the cohort of patients with AIH, we examined the impact of immunosuppressive treatment (IST) and cirrhosis on cancer risks. RESULTS: The 10-year risk of any cancer was 13.6% (95% confidence interval [CI] 11.7-15.6) in patients with AIH with an RR of 1.5 (95% CI 1.3-1.7) compared with controls. Patients with AIH had a 10-year risk of 0.5% (95% CI 0.2-1.1) for hepatocellular carcinoma. The 10-year risk was 1.6% (95% CI 1.0-2.5) for colorectal cancer (RR: 2.1 [95% CI 1.3-3.5]) and 4.0% (95% CI 3.0-5.3) for nonmelanoma skin cancer (RR: 1.8 [95% CI 1.3-2.5]). Among patients with AIH, the risk of cancer was higher for those with cirrhosis (hazard ratio: 1.3 [95% CI 1.0-1.7]), and it also increased 1.05-fold (95% CI 1.0-1.1) for every year the patient was on IST. DISCUSSION: AIH was associated with a 1.5-fold increased 10-year risk of cancer compared with age- and sex-matched controls. Among patients with AIH, the risk of cancer was higher for those with cirrhosis, and it also increased slightly with longer duration of IST.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Jensen MD, Jepsen P, Vilstrup H, et al. Increased Cancer Risk in Autoimmune Hepatitis: A Danish Nationwide Cohort Study. Am J Gastroenterol. 2022. PMID: 34622808. doi:10.14309/ajg.0000000000001525

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。